Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin

ONCOLOGY

Volumn 11, Issue 9 SUPPL. 10, 1997, Pages 35-39

  Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; UFT;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; UNITED STATES;

ADMINISTRATION, ORAL; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASMS; TEGAFUR; TETRAHYDROFOLATES; URACIL;

EID: 0030833022     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Fujii S, Ikenaka K, Fukushima M, et al: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil 1-(2-tetrahydryofuryl) 5-fluorouracil. Kagakn Kyolio 69:763-772, 1978.
2. Taguchi T, Nakano Y, Fujita M, et al: Clinical studies of the anticancer activity of FT-207. Jpn J Cancer Clinics 18:550-553, 1972.
3. Fujii S, Kitano S, Ikenaka K, et al: Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Cliemotlier 6:377-384, 1979.